- Home
- OLP vs EYPT Comparison
OLP vs EYPT Comparison
Compare OLP & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLP
- EYPT
- Stock Information
- Founded
- OLP 1982
- EYPT 1987
- Country
- OLP United States
- EYPT United States
- Employees
- OLP N/A
- EYPT N/A
- Industry
- OLP Real Estate Investment Trusts
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- OLP Real Estate
- EYPT Industrials
- Exchange
- OLP Nasdaq
- EYPT Nasdaq
- Market Cap
- OLP N/A
- EYPT 489.4M
- IPO Year
- OLP N/A
- EYPT 2005
- Fundamental
- Price
- OLP $25.75
- EYPT $7.69
- Analyst Decision
- OLP Strong Buy
- EYPT Strong Buy
- Analyst Count
- OLP 1
- EYPT 8
- Target Price
- OLP $28.00
- EYPT $25.71
- AVG Volume (30 Days)
- OLP 46.6K
- EYPT 665.0K
- Earning Date
- OLP 03-04-2025
- EYPT 03-06-2025
- Dividend Yield
- OLP 7.06%
- EYPT N/A
- EPS Growth
- OLP 51.11
- EYPT N/A
- EPS
- OLP 1.63
- EYPT N/A
- Revenue
- OLP $89,142,000.00
- EYPT $45,713,000.00
- Revenue This Year
- OLP N/A
- EYPT N/A
- Revenue Next Year
- OLP $4.71
- EYPT N/A
- P/E Ratio
- OLP $15.65
- EYPT N/A
- Revenue Growth
- OLP N/A
- EYPT 7.50
- 52 Week Low
- OLP $19.75
- EYPT $6.90
- 52 Week High
- OLP $30.45
- EYPT $30.99
- Technical
- Relative Strength Index (RSI)
- OLP 42.45
- EYPT 41.66
- Support Level
- OLP $25.08
- EYPT $7.58
- Resistance Level
- OLP $25.93
- EYPT $8.16
- Average True Range (ATR)
- OLP 0.53
- EYPT 0.55
- MACD
- OLP 0.09
- EYPT -0.07
- Stochastic Oscillator
- OLP 52.99
- EYPT 3.06
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.